Olink® Insight Unveils Open-access Map of the Human Proteome, Aiding Biomarker Discovery and Understanding of Disease
- None.
- None.
Insights
Olink Holding AB's release of a comprehensive protein-disease risk data library represents a significant advancement in the field of proteomics, which could have profound implications for the development of personalized medicine. The integration of this data with longitudinal healthcare information marks a leap forward in understanding the complex interactions between proteins and disease progression.
The implications for companies operating within the biotechnology and pharmaceutical sectors are substantial. The ability to access a vast array of protein-disease associations will likely accelerate the discovery of biomarkers, which are important for the development of targeted therapies. This could, in turn, lead to more efficient R&D processes and potentially reduce the time and cost associated with bringing new treatments to market.
For investors, the value proposition lies in the potential for this data to translate into new product pipelines or enhance existing ones. Companies that leverage such data effectively may gain a competitive edge, translating into potential growth opportunities. However, it's essential to monitor how Olink and its competitors capitalize on these resources to maintain a balanced investment perspective.
The unveiling of Olink's open-access data library is poised to disrupt the healthcare industry by enhancing disease understanding and treatment approaches. The scale of the UK Biobank Pharma Proteomics Project, combined with Olink's technology, has yielded an extensive dataset that could be instrumental in identifying novel therapeutic targets.
From an industry standpoint, the ability to pinpoint disease-specific biomarkers with greater precision is expected to catalyze the development of personalized healthcare solutions. Healthcare providers might soon be able to offer more tailored treatments based on an individual's protein expression profile, potentially improving patient outcomes and reducing healthcare costs over the long term.
However, the accessibility of such data may also raise concerns about data privacy and the ethical use of genetic information. Companies in the healthcare sector will need to navigate these challenges carefully to maintain public trust and ensure compliance with regulatory standards.
The introduction of Olink Insight as a user-friendly platform for non-data scientists is a noteworthy development in the democratization of complex data analysis. By simplifying the process of extracting meaningful insights from large datasets, Olink is potentially broadening the scope of research and development across various scientific disciplines.
For businesses, this tool could translate into cost savings by reducing the need for specialized data analysis personnel and resources. Additionally, the speed at which researchers can now identify significant protein-disease associations may lead to quicker hypothesis generation and validation, thus streamlining the research process.
It is important to consider, though, that the ease of access to such data could lead to an increase in the volume of research, potentially resulting in information overload. Ensuring the quality and reproducibility of findings derived from Olink Insight will be important for maintaining the integrity of research conducted using this tool.
UPPSALA, Sweden, April 02, 2024 (GLOBE NEWSWIRE) -- Olink Holding AB (publ) (Nasdaq: OLK) today announced the availability of an open access data library consisting of over 300,000 protein-disease risk associations, giving researchers a powerful new tool for revealing the biological mechanisms underlying 106 human diseases.
In April 2023, the UK Biobank Pharma Proteomics Project (UKB-PPP) released data produced from over 50,000 samples analyzed using the Olink® Explore platform. The UKB-PPP is the largest population-scale proteomics study to date, yielding an unprecedented view into the biology of diseased and healthy individuals over a 10-year period. By combining protein measurements with longitudinal healthcare data for each of the individuals, Olink derived the estimated effects of ~3,000 proteins on the future risk of disease.
The derived data library is available within Olink Insight. Olink Insight is a free, web-based platform that puts the results of advanced computational data analysis into the hands of non-data scientists. In just a few clicks scientists can quickly go from raw experimental results to the identification of significant hits, overlaid with information on tissue specificity, disease associations, and variability in normal cohorts.
A detailed presentation of how scientists can leverage this data for uncovering disease-specific biomarkers or elucidating the involvement of biomarkers across multiple diseases will be presented in a technical webinar on April 24, 2024.
The disease risk data contained in the library will enable researchers to better understand critical drivers across a broad spectrum of diseases from inflammatory pathways to prostate cancer. The data are a powerful tool for exploring the role of key proteins such as FCRL2 in critical processes like B cell development and chronic lymphocytic leukemia (CLL).
“UK Biobank is the world’s leading biomedical data resource, powering research that will improve the health of the public across the globe,” said Dr. Lucy Burkitt-Gray, Lead Data Analyst, UK Biobank. “The Olink findings correlating protein levels to disease risk are one of many prime examples of how the large-scale UK Biobank cohort data on half a million volunteers is contributing to our understanding of how protein expression affects health.”
“We are tremendously excited to add this rich dataset, revealing important protein-disease associations, to the Olink Insight platform which represents a significant realization of the potential of the UK Biobank data while also further reducing the barrier to access,” says Ida Grundberg, Chief Scientific Officer at Olink. “These data provide essential insights into the biology of disease, allowing researchers to better understand their findings and accelerate the understanding of disease progressions and treatment effects.”
The open-access disease risk data library is another example of Olink’s active partnership with the scientific community to advance our understanding of how individual differences impact disease progression and treatment. Together with industry leading proteomics products and services, Olink is committed to delivering complete end to end solutions that help researchers realize the promise of precision medicine.
Learn more about the open-access disease data in the Olink webinar.
Learn more about Olink Insight at Insight.olink.com.
Learn more about Olink’s next-generation proteomics technologies at Olink.com.
Investor contact
Oskar Hjelm
Chief Financial Officer
Mobile: +46 733502932
oskar.hjelm@olink.com
Media contact
Michael B. Gonzales, PhD
Vice President, Global Marketing
Mobile: +1 415 308 6467
michael.gonzales@olink.com
About Olink
Olink Holding AB (Nasdaq: OLK) is a company dedicated to accelerating proteomics together with the scientific community, across multiple disease areas to enable new discoveries and improve the lives of patients. Olink provides a platform of products and services which are deployed across major pharmaceutical companies and leading clinical and academic institutions to deepen the understanding of real-time human biology and drive 21st century healthcare through actionable and impactful science. The Company was founded in 2016 and is well established across Europe, North America and Asia. Olink is headquartered in Uppsala, Sweden.
Forward-looking statements
This release may contain forward-looking statements within the meaning of applicable securities laws, including the U.S. Private Securities Litigation Reform Act of 1995, as amended, including, without limitation, statements regarding Olink’s strategy, business plans and focus. The words “may,” “will,” “could,” “would,” “should,” “expect,” “plan,” “anticipate,” “intend,” “believe,” “estimate,” “predict,” “project,” “potential,” “continue,” “target” and similar expressions are intended to identify forward-looking statements, although not all forward-looking statements contain these identifying words. Any forward-looking statements in this press release are based on management’s current expectations and beliefs as of the date hereof and are subject to a number of risks, uncertainties and important factors that may cause actual events or results to differ materially from those expressed or implied by any forward-looking statements contained in this press release, including, without limitation, those related to Olink’s business, operations, supply chain, strategy, goals and anticipated timelines, including for the delivery of Olink Explore 3072 and the expansion of the Explore platform, competition, and other risks identified in the section entitled “Risk Factors” in Olink’s Registration Statement on Form F-1, as amended (File No. 333-253818) filed with the U.S. Securities and Exchange Commission (SEC) and in the other filings, reports, and documents Olink files with the SEC from time to time. Olink expressly disclaims any obligation to update any forward-looking statements in this release to reflect any change in its expectations with regard thereto or any change in events, conditions or circumstances on which any such statement is based, unless required by law or regulation.
FAQ
What did Olink Holding AB announce recently?
What is the ticker symbol for Olink Holding AB?
What is the purpose of the data library launched by Olink Holding AB?
When will a technical webinar showcasing the data library be held?
What is the significance of the UK Biobank Pharma Proteomics Project (UKB-PPP) data release?
